PA1-732

antibody from Invitrogen Antibodies

Targeting: ARRB2 ARR2, BARR2, DKFZp686L0365

Western blot

Antibody data

Submit

Validation data

Product number: PA1-732 - Provider product page
Provider: Invitrogen Antibodies
Product name: beta-Arrestin 2 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: PA1-732 detects beta-Arrestin 2 in rat, human and bovine samples. PA1-732 has been successfully used in Western blot procedures. By Western blot, this antibody detects ~49 kDa and ~47 kDa proteins representing pan Arrestin in rat and bovine retina as well as rat brain samples. The PA1-732 immunogen is a synthetic peptide corresponding to residues C D(384) D I V F E D F A R L R L K(397) of human beta-arrestin 2. This peptide (Cat. # PEP-281) is available for use in neutralization and control experiments.
Reactivity: Human, Mouse, Rat, Bovine
Host: Rabbit
Isotype: IgG
Vial size: 100 µg
Concentration: 1 mg/mL
Storage: -20°C, Avoid Freeze/Thaw Cycles

ARRB2 protein structure - PA1-732 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of beta-Arrestin 2 was performed using 70% confluent log phase HEK293 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with beta-Arrestin 2 Rabbit Polyclonal Antibody (Product # PA1-732) at 2µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of beta-Arrestin 2 was performed using 70% confluent log phase HEK293 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with beta-Arrestin 2 Rabbit Polyclonal Antibody (Product # PA1-732) at 2µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (Heavy Chain) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 8 a beta-arrestin 2 before (CHF) and after LVAD therapy (CHF+LVAD) as compared to non-failing ventricles (NF). beta-arrestin 2 expression was determined by immunoblot (western blot) analysis and referred to a standard, respectively, whose densitometric value was set 1 by default. The value on the y -axis, therefore, reflects the percentage of each parameter's immunoblot band density in relation to this default value. AU arbitrary unit, CHF congestive heart failure, LVAD left ventricular assist device, NF non-failing myocardial tissue specimen. b beta-arrestin 2 before (CHF) and after LVAD therapy (CHF+LVAD) in the subgroup of ICM patients as compared to non-failing ventricles (NF), left ( n = 8). beta-arrestin 2 before (CHF) and after LVAD therapy (CHF+LVAD) in the subgroup of 10 patients with a duration of LVAD therapy above the median value as compared to non-failing ventricles (NF), right. AU arbitrary unit, CHF congestive heart failure, ICM ischemic cardiomyopathy, LVAD left ventricular assist device, NF non-failing myocardial tissue specimen

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation outputs used to assess JNK3-JIP1-beta-arrestin2-PSD95 colocalization in primary hippocampal neurons. ( A ) PSD95 was immunoprecipitated from the cell lysate homogenate using PSD95 antibody, and immune complexes were analyzed for the presence of JNK3, JIP1, and beta-arrestin2. Immunoprecipitation with IgG antibody was used as a control. ( B ) JNK3 was immunoprecipitated from the cell lysate homogenate using JNK3-specific antibody, separated by SDS-PAGE, and analyzed via Western blot with anti-PSD95, anti-JIP1, and anti-beta-arrestin2 antibodies. Immunoprecipitation with IgG antibody was used as a control. * indicates non-specific bands.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation outputs used to assess JNK3-JIP1-beta-arrestin2-PSD95 interactions at the synapse. ( A ) Western blots performed on total brain homogenate and Triton-insoluble fraction (TIF) reveal the different amounts of JNK3, JIP1, beta-arrestin2, and PSD95 in the two extracts analyzed. Synaptophysin was used as a control for the purity of the TIF preparation. ( B ) JIP1 was immunoprecipitated from the TIF using JIP1 antibody, and immune complexes were analyzed for the presence of JNK3 (rabbit). Immunoprecipitation with IgG antibody was used as a control. PSD95 was immunoprecipitated from the TIF using PSD95-specific antibody, separated by SDS-PAGE, and analyzed with Western blot with anti-PSD95, anti-JNK3 (mouse), and anti-JIP1 antibodies. Immunoprecipitation with IgG antibody was used as a control. ( C ) JNK3 was immunoprecipitated from the TIF using the JNK3 antibody, and immune complexes were analyzed for the presence of beta-arrestin2 and JNK3 (rabbit). Immunoprecipitation with IgG antibody was used as a control. beta-arrestin2 was immunoprecipitated from the TIF using beta-arrestin2-specific antibody, separated by SDS-PAGE, and analyzed by Western blot with anti-PSD95, anti-JNK3, and anti-beta-arrestin2 antibodies. Immunoprecipitation with IgG antibody was used as a control. * indicates non-specific bands.